Observational study of SorbaView® 2000, SorbaView® Ultimate and SecureView® Port AFZ Dressings used on Central Venous Catheters in Eleven Italian Oncology, Hematology and Pain Centers

L. Orsino (Study Manager) et al.
The Journal of the Association for Vascular Access (March 2009); 14 (1): 14-19

Abstract
Observational study of SorbaView® 2000, SorbaView® Ultimate and SecureView® Port AFZ dressings used on Central Venous Catheters in 11 Italian Oncology, Hematology and Pain Centers. Dressing care is one of the nursing challenges that is more and more frequent in the management of central venous catheters (CVCs). Our intention with this observational study was to study the efficacy and tolerability of the latest generation devices recently introduced in Italy. The study was performed on 435 patients; including 293 carriers of totally implantable CVCs and 142 carriers of tunneled and non-tunneled CVCs. In 90% of 311 patients with scheduled therapy of greater than seven days, the dressing adhered completely, at the end of seven days and up to 10 days. In 10% of all 435 patients the dressing became partially detached at between greater than one day and less than 10 days, but not enough to justify dressing change. Of the 10% that partially detached with dwell time greater than one day and less than four days, most occurred in Hematology. A cumulative total of 1,391 dressings were applied.

At the conclusion of the study, 84% of patients reported that they were satisfied with the use of the SorbaView® 2000, SorbaView® Ultimate and SecureView® Port AFZ dressings.

Summary
This study was performed at eleven Italian Oncology, Hematology and Pain centers. The intention of this observational study was to demonstrate the durability and tolerability of the latest generation of SorbaView dressings introduced in Italy. Specific dressings were the Sorbaview 2000, Sorbaview Ultimate, and Secureview Port AFZ dressings. The dressings held up an amazing 92.66% of the time and 83.9% of the clinicians approved of the performance and comfort of the dressing.

Key Points
• 435 patients enrolled
• Three dressing products were used: Sorbaview 2000, Sorbaview Ultimate, and SecureView AFZ
• In total, 1,391 dressings were applied
• 1,291 (92.66%) adhered for the prescribed therapy
• 94 (6.75%) detached but did not need to be replaced
• 8 were completely detached (0.57%)
• 83.9% of Clinicians expressed approval of the product and how the dressings assisted with hygiene, daily activities, and quality of life of the patient